Antinociceptive effect of N-(9,13b-dihydro-1H-dibenzo[c,f]imidazo[1,5-a]azepin-3-yl)-2-hydroxybenzamide on different pain models in mice
DOI:
https://doi.org/10.1590/s2175-97902022e20030%20Keywords:
N-(9,13b-dihydro-1H-dibenzo[c,f]imidazo[1,5-a]azepin-3-yl)-2-hydroxybenzamide (DDIAHB), Antinociception, Spinal cord, Signal moleculesAbstract
N-(9,13b-dihydro-1H-dibenzo[c,f]imidazo[1,5-a]azepin-3-yl)-2-hydroxybenzamide (DDIAHB) is a new drug developed through molecular modelling and rational drug design by the molecular association of epinastine and salicylic acid. The present study was designed to assess the possible antinociceptive effects of DDIAHB on different pain models in male ICR mice. DDIAHB exerted the reductions of writhing numbers and pain behavior observed during the second phase in the formalin test in a dose-dependent manner. Moreover, DDIAHB increased the latency in the hot-plate test in a dose-dependent manner. Furthermore, intragastric administration DDIAHB caused reversals of decreased pain threshold observed in both streptozotocin-induced diabetic neuropathy and vincristine-induced peripheral neuropathy models. Additionally, intragastric pretreatment with DDIAHB also caused reversal of decreased pain threshold observed in monosodium urate-induced pain model. We also characterized the possible signaling molecular mechanism of the antinociceptive effect-induced by DDIAHB in the formalin model. DDIAHB caused reductions of spinal iNOS, p-STAT3, p-ERK and p-P38 levels induced by formalin injection. Our results suggest that DDIAHB shows an antinociceptive property in various pain models. Moreover, the antinociceptive effect of DDIAHB appear to be mediated by the reductions of the expression of iNOS, p-STAT3, p-ERK and p-P38 levels in the spinal cord in the formalin-induced pain model.
Downloads
References
Adamus W, Oldigs-Kerber J, Lohmann H. Pharmacodynamics of the new H1-antagonist 3-amino-9,13b-dihydro-1H-dibenz[c,f]imidazo[1,5-a]azepine hydrochloride in volunteers. Arzneimittelforschung. 1987;37(5):569-572.
Bonin RP, Bories C, De Koninck Y. A simplified up-down method (SUDO) for measuring mechanical nociception in rodents using von Frey filaments. Mol Pain. 2014;10(1):26.
Cao JL, Ding HL, He JH, Zhang LC, Duan SM, Zeng YM. The spinal nitric oxide involved in the inhibitory effect of midazolam on morphine-induced analgesia tolerance. Pharmacol Biochem Behav. 2005;80(3):493-503.
Crown ED, Gwak YS, Ye Z, Johnson KM, Hulsebosch CE. Activation of p38 MAP kinase is involved in central neuropathic pain following spinal cord injury. Exp Neurol. 2008;213(2):257-67.
Dalbeth N, Haskard D. Mechanisms of inflammation in gout. Rheumatology (Oxford). 2005;44(9):1090-1096.
Descalzi G, Fukushima H, Suzuki A, Kida S, Zhuo M. Genetic enhancement of neuropathic and inflammatory pain by forebrain upregulation of CREB-mediated transcription. Mol Pain . 2012;8:90.
Dogrul A, Gülmez SE, Deveci MS, Gul H, Ossipov MH, Porreca F, et al. The local antinociceptive actions of nonsteroidal antiinflammatory drugs in the mouse radiant heat tail-flick test. Anesth Analg. 2007;104(4):927-935.
Eddy NB, Leimbach D. Synthetic analgesics. II. Dithienylbutenyl-and dithienylbutylamines. J Pharmacol Exp Ther. 1953;107(3):385-393.
Geronikolou SA. Treatment of gout in a recently published 9th century manuscript of Rhazes. Vesalius. 2014;20(2):95-98.
Hung AL, Lim M, Doshi TL. Targeting cytokines for treatment of neuropathic pain. Scand J Pain. 2017;17:287-293.
Hunskaar S, Fasmer OB, Hole K. Formalin test in mice, a useful technique for evaluating mild analgesics. J Neurosci Methods. 1985;14(1):69-76.
Hunskaar S, Hole K. The formalin test in mice: dissociation between inflammatory and non-inflammatory pain. Pain. 1987;30(1):103-114.
Jin SX, Zhuang ZY, Woolf CJ, Ji RR. p38 mitogen-activated protein kinase is activated after a spinal nerve ligation in spinal cord microglia and dorsal root ganglion neurons and contributes to the generation of neuropathic pain. J Neurosci. 2003;23(10):4017-22.
Kanai K-i, Asano K, Watanabe S, Kyo Y, Suzaki H. Epinastine hydrochloride antagonism against interleukin-4-mediated T cell cytokine imbalance in vitro. Int Arch Allergy Immunol. 2006;140(1):43-52.
Katerinaki E, Haycock JW, Lalla R, Carlson KE, Yang Y, Hill RP, et al. Sodium salicylate inhibits TNF-α-induced NF-κB activation, cell migration, invasion and ICAM-1 expression in human melanoma cells. Melanoma Res. 2006;16(1):11-22.
Khan J, Hassun H, Zusman T, Korczeniewska O, Eliav E. Interleukin-8 levels in rat models of nerve damage and neuropathic pain. Neurosci Lett. 2017;657:106-112.
Kim HM, Lee EH, Shin TK, Chung CK, An N. Inhibition of the induction of the inducible nitric oxide synthase in murine brain microglial cells by sodium salicylate. Immunology. 1998;95(3):389.
Kohyama T, Takizawa H, Akiyama N, Sato M, Kawasaki S, Ito K. A novel antiallergic drug epinastine inhibits IL-8 release from human eosinophils. Biochem Biophys Res Commun. 1997;230(1):125-128.
Koster R, Anderson M, Beer EJ. Acetic acid for analgesic screening. Fed proc. 1959;18:412.
Kwon MS, Shim EJ, Seo YJ, Choi SS, Lee JY, Lee HK, et al. Effect of aspirin and acetaminophen on proinflammatory cytokine-induced pain behavior in mice. Pharmacol. 2005;74(3):152-156.
Lan X, Liu R, Sun L, Zhang T, Du G. Methyl salicylate 2-O-β-D-lactoside, a novel salicylic acid analogue, acts as an anti-inflammatory agent on microglia and astrocytes. J Neuroinflammation. 2011;8(1):98.
Lanier BQ, Finegold I, D’Arienzo P, Granet D, Epstein AB, Ledgerwood GL. Clinical efficacy of olopatadine vs epinastine ophthalmic solution in the conjunctival allergen challenge model. Curr Med Res Opin. 2004;20(8):1227-1233.
Lee JM, Damodar K, Lee Y, Lee J, Jeon SH, Lee JT. Synthesis and Biological Assay of Hybrids Between Epinastine and Salicylic Acid as Promising Nitric Oxide Production Inhibitors. Bull Korean Chem Soc. 2019;40:735-740.
Lee MJ, Jang M, Jung HS, Kim SH, Cho IH. Ethyl pyruvate attenuates formalin-induced inflammatory nociception by inhibiting neuronal ERK phosphorylation. Mol Pain . 2012;8:40.
Linglu D, Yuxiang L, Yaqiong X, Ru Z, Lin M, Shaoju J, et al. Antinociceptive effect of matrine on vincristine-induced neuropathic pain model in mice. Neurol Sci. 2014;35(6):815-821.
Mah FS, Rosenwasser LJ, Townsend WD, Greiner JV, Bensch G. Efficacy and comfort of olopatadine 0.2% versus epinastine 0.05% ophthalmic solution for treating itching and redness induced by conjunctival allergen challenge. Curr Med Res Opin . 2007;23(6):1445-1452.
Martinon F, Pétrilli V, Mayor A, Tardivel A, Tschopp J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature. 2006;440(7081):237.
Mizuguchi H, Hatano M, Matsushita C, Umehara H, Kuroda W, Kitamura Y et al. Repeated pre-treatment with antihistamines suppresses transcriptional up-regulations of histamine H-1 receptor and interleukin-4 genes in toluene-2, 4-diisocyanate-sensitized rats. J Pharmacol Sci. 2009;109(2):324-324.
Mollanazar NK, Smith PK, Yosipovitch G. Mediators of chronic pruritus in atopic dermatitis: getting the itch out? Clin Rev Allergy Immunol. 2016;51(3):263-292.
Nemoto W, Ogata Y, Nakagawasai O, Yaoita F, Tanado T, Tan-No K. The intrathecal administration of losartan, an AT1 receptor antagonist, produces an antinociceptive effect through the inhibiton of p38 MAPK phosphorylation in the mouse formalin test. Neurosci Lett . 2015;585:17-22.
Otsuka A, Honda T, Doi H, Miyachi Y, Kabashima K. An H1-histamine receptor antagonist decreases serum interleukin-31 levels in patients with atopic dermatitis. Br J Dermatol. 2011;164(2):455-456.
Otsuka A, Tanioka M, Nakagawa Y, Honda T, Ikoma A, Miyachi Y, et al. Effects of cyclosporine on pruritus and serum IL-31 levels in patients with atopic dermatitis. Eur J Dermatol. 2011;21(5):816-817.
Pereira PAT, Bini D, Bovo F, Faccioli LH, Monteiro MC. Neutrophils influx and proinflammatory cytokines inhibition by sodium salicylate, unlike aspirin, in Candida albicans-induced peritonitis model. Folia Microbiol (Praha). 2016;61(4):337-346.
Perez-G M, Melo M, Keegan AD, Zamorano J. Aspirin and salicylates inhibit the IL-4-and IL-13-induced activation of STAT6. J Immunol. 2002;168(3):1428-1434.
Shibata M, Ohkubo T, Takahashi H, Inoki R. Modified formalin test: characteristic biphasic pain response. Pain . 1989;38(3):347-352.
Shtivelband M, Juneja H, Lee S, Wu K. Aspirin and salicylate inhibit colon cancer medium-and VEGF-induced endothelial tube formation: correlation with suppression of cyclooxygenase-2 expression. J Thromb Haemost. 2003;1(10):2225-2233.
Sim YB, Park SH, Kang YJ, Kin SS, Kim CH, Kim SJ et al. Repaglinide, but not nateglinide administered supraspinally and spinally exerts an anti-diabetic action in d-glucose fed and streptozotocin-treated mouse models. Korean J Physiol Pharmacol. 2013;17(6):493-497.
Tjølsen A, Berge O-G, Hunskaar S, Rosland JH, Hole K. The formalin test: an evaluation of the method. Pain . 1992;51(1): 5-17.
Wang B, Liu S, Fan B, Xu X, Chen Y, Lu R et al. PKM2 is involved in neuropathic pain by regulating ERK and STAT3 activation in rat spinal cord. J Headache Pain . 2018;19(1):7.
Wang K, Song F, Wang H, Wang JH, Sun Y. Quetiapine Attenuates the Neuroinflammation and Executive Function Deficit in Streptozotocin-Induced Diabetic Mice. Mediators Inflamm. 2019;2019:1236082.
Wang S, Li A, Guo S. Ligustrazine attenuates neuropathic pain by inhibition of JAK/STAT3 pathway in a rat model of chronic constriction injury. Pharmazie. 2016;71(7):408-412.
Wang Z, Brecher P. Salicylate inhibition of extracellular signal-regulated kinases and inducible nitric oxide synthase. Hypertension. 1999;34(6):1259-1264.
Woo HR, Damodar K, Lee Y, Lim SS, Jeon S H, Lee JT. Discovery of epinastine-NSAID hybrids as potential anti- inflammatory agents: Synthesis and in vitro nitric oxide production inhibitory activity study. J Korean Chem Society, 2020;64(2):79-83.
Xu H, Gong N, Chen L, Xu TL. Sodium salicylate reduces gamma aminobutyric acid-induced current in rat spinal dorsal horn neurons. Neuroreport. 2005;16(8):813-816.
Downloads
Published
Issue
Section
License
Copyright (c) 2022 Brazilian Journal of Pharmaceutical Sciences
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content of the journal, except where identified, is licensed under a Creative Commons attribution-type BY.
The on line journal has open and free access.
